An increase of more than 500 pg/ml VEGFA and a decrease of more than 9 % of the pre-therapeutic value of TIMP2 were significantly associated with a higher risk of early recurrence ( RR = 8.5 , 95 % CI = 1.8-39 .8 and RR = 11.0 , 95 % CI = 2.5-48 .2 , respectively ) .